U.S. markets close in 4 hours 10 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
194.00-0.38 (-0.20%)
A partir del 11:50AM EDT. Mercado abierto.

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
https://www.biogen.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - General
Empleados a tiempo completo7,570

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Christopher A. ViehbacherPresident, CEO & Director487.94kN/D1961
Mr. Michael R. McDonnell CPAExecutive VP & CFO2.12MN/D1964
Ms. Nicole MurphyHead of Pharmaceutical Operations & Technology1.46MN/DN/D
Ms. Susan H. Alexander Esq.Executive VP & Chief Legal Officer2.2MN/D1957
Dr. Ginger GregoryExecutive VP & Chief Human Resources Officer1.59MN/D1968
Ms. Robin C. KramerSenior VP & Chief Accounting OfficerN/DN/D1966
Mr. Charles E. TrianoSenior VP & Head of Investor RelationsN/DN/DN/D
Ms. Natacha GassenbachChief Communication Officer & Head of Corporate AffairsN/DN/DN/D
Mr. Adam Keeney Ph.D.Executive VP & Head of Corporate DevelopmentN/DN/DN/D
Ms. Alisha A. AlaimoPresident & Head of North AmericaN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Biogen Inc. a partir del 1 de abril de 2024 es 6. Las puntuaciones principales son Auditoría: 9; Junta: 5; Derechos del accionista: 2; Compensación: 9.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.